Data from Pharmawand - Curated by EPG Health - Date added 14 September 2018

Novartis has announced new data from multiple real-world sources in moderate-to-severe plaque psoriasis , which confirm Cosentyx (secukinumab) efficacy and safety in clinical practice is comparable to previously reported clinical studies. Real-world evidence also confirmed the additional benefits of Cosentyx with PROSPECT, the largest prospective real-world analysis on Cosentyx to date , demonstrating a pronounced improvement in quality of life in a real-world setting (59% of patients at 24 weeks experience no or little impact of their skin disease on their quality of life). Cosentyx is the first and only fully-human treatment that specifically inhibits IL-17A. A large program of real-world evidence was presented for the first time at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.

Additional real-world data presented at EADV showed that 87% of bio-naive psoriasis patients remain on Cosentyx at 12 months, further supporting the use of Cosentyx in real-world settings. "For both psoriasis patients and doctors, these data confirm that Cosentyx clinical data profile translates into real-world benefits," said Dr. Richard G.B. Langley MD, RPC(C), Professor of Dermatology and Director of Research, Dalhousie University, Halifax, Nova Scotia, Canada. "In the everyday management of psoriasis, this provides added reassurance that with Cosentyx, patients achieve and maintain high levels of skin clearance and improved quality of life."

At EADV 2017, Novartis presented 5-year data from the Phase III SCULPTURE study reinforcing Cosentyx long term skin clearance and safety. Cosentyx is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in Phase III in psoriasis. Landmark data show that PASI 90 and PASI 100 response rates were nearly 100% maintained with Cosentyx from Year 1 to Year 5 in patients with moderate-to-severe plaque psoriasis. These data add to the growing body of evidence showing the unique position of Cosentyx as the first and only fully-human IL-17A inhibitor. To date, Cosentyx has been prescribed to more than 160,000 patients worldwide.The clinical Phase III program has demonstrated long-term efficacy and a proven safety profile of Cosentyx to treat moderate-to-severe psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). In May, Novartis announced its plan to initiate the ARROW trial to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya) as the 100th study with Cosentyx.

About XPOSE, PROSPECT, CORRONA, and PURE : These findings are from analysis of real-world data from 2 non-interventional studies and 2 registries across multiple countries: Data from the Canadian patient support program XPOSE (3,020 patients with moderate-to-severe psoriasis) were analysed for the patients where efficacy data was reported by a physician (192 patients); PROSPECT is the largest real-world study of Cosentyx in psoriasis, involving 2,002 patients in Germany (905 patients followed up for 24 weeks to date); CORRONA is an independently run registry of patients with psoriasis from the United States (306 patients initiated Cosentyx at enrollment, with effectiveness data available to date for 118 patients for 6 months, and 56 patients for 12 months); and PURE a prospective, international, observational, two cohort registry of adult patients with moderate-to-severe chronic plaque psoriasis in Latin America and Canada (397 patients, with efficacy data available to date for 124 patients for 12 months, and 59 patients for 18 months).

Real-world evidence (RWE) is clinical evidence based upon data taken from a variety of sources in daily life, outside of the clinical trial setting. RWE helps to bridge the gap in knowledge that exists between clinical trials and clinical practice, making it an important complement to long-term data from clinical trials.

Cosentyx has a broad head-to-head study program that includes FIXTURE, CLEAR, CLARITY, SURPASS and EXCEED clinical superiority trials. In May 2018, Novartis announced its plan to initiate the ARROW trial to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya) in treating recalcitrant plaques resistant to ustekinumab. This study is the 100th trial with Cosentyx in the last 10 years, adding to the wealth of data. The clinical Phase III program of Cosentyx has demonstrated long term efficacy and a proven safety profile of Cosentyx to treat moderate-to-severe psoriasis, PsA and AS..


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

EADV 2018 Highlights

EADV 2018 Highlights

EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.

Atopic Dermatitis

Atopic Dermatitis

The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.

Load more

Related Content